Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma

被引：22

作者：

Collins, Graham P. ^{[1
]}

Parker, Anne N. ^{[2
]}

Pocock, Christopher ^{[3
]}

Kayani, Irfan ^{[4
]}

Sureda, Anna ^{[5
]}

Illidge, Tim ^{[6
]}

Ardeshna, Kirit ^{[7
]}

Linch, David C. ^{[7
,8
]}

Peggs, Karl S. ^{[7
,8
]}

机构：

[1] Churchill Hosp, Oxford Canc & Haematol Ctr, Dept Haematol, Oxford OX3 7LJ, England

[2] Beatson West Scotland Canc Ctr, HPC Transplant Programme, Glasgow, Lanark, Scotland

[3] East Kent Hosp NHS Trust, Dept Haematol, Canterbury, Kent, England

[4] Univ Coll London Hosp NHS Trust, Dept Nucl Med, London, England

[5] Univ Cambridge, Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England

[6] Univ Manchester, Christie Hosp, Inst Canc Sci, Manchester, Lancs, England

[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England

[8] UCL, Inst Canc, Dept Haematol, London WC1E 6BT, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 164卷 / 01期

关键词：

Hodgkin lymphoma; relapse; chemotherapy; transplantation; STEM-CELL-TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; INVOLVED FIELD RADIOTHERAPY; BLOOD PROGENITOR-CELL; SALVAGE THERAPY; BRENTUXIMAB VEDOTIN; PROGNOSTIC-FACTORS; MINI-BEAM; RADIATION-THERAPY;

D O I：

10.1111/bjh.12582

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：39 / 52

页数：14

共 89 条

[1] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[2] ESHAP is an active regimen for relapsing Hodgkin's disease [J].

Aparicio, J ;

Segura, A ;

Garcerá, S ;

Oltra, A ;

Santaballa, A ;

Yuste, A ;

Pastor, M .

ANNALS OF ONCOLOGY, 1999, 10 (05) :593-595

[3] Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].

Baetz, T ;

Belch, A ;

Couban, S ;

Imrie, K ;

Yau, J ;

Myers, R ;

Ding, K ;

Paul, N ;

Shepherd, L ;

Iglesias, J ;

Meyer, R ;

Crump, M .

ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767

[4] Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 [J].

Bartlett, N. L. ;

Niedzwiecki, D. ;

Johnson, J. L. ;

Friedberg, J. W. ;

Johnson, K. B. ;

van Besien, K. ;

Zelenetz, A. D. ;

Cheson, B. D. ;

Canellos, G. P. .

ANNALS OF ONCOLOGY, 2007, 18 (06) :1071-1079

[5] Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma [J].

Benekli, M. ;

Smiley, S. L. ;

Younis, T. ;

Czuczman, M. S. ;

Hernandez-Ilizaliturri, F. ;

Bambach, B. ;

Battiwalla, M. ;

Padmanabhan, S. ;

McCarthy, P. L., Jr. ;

Hahn, T. .

BONE MARROW TRANSPLANTATION, 2008, 41 (07) :613-619

[6] Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma [J].

Biswas, Tithi ;

Culakova, Eva ;

Friedberg, Jonathan W. ;

Kelly, Jennifer L. ;

Dhakal, Sughosh ;

Liesveld, Jane ;

Phillips, Gordon L. ;

Constine, Louis S. .

RADIOTHERAPY AND ONCOLOGY, 2012, 103 (03) :367-372

[7] Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [J].

Bonfante, V ;

Santoro, A ;

Viviani, S ;

Devizzi, L ;

Balzarotti, M ;

Soncini, F ;

Zanini, M ;

Valagussa, P ;

Bonadonna, G .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :528-534

[8] Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry [J].

Brice, P ;

Bouabdallah, R ;

Moreau, P ;

Divine, M ;

Andre, M ;

Aoudjane, M ;

Fleury, J ;

Anglaret, B ;

Baruchel, A ;

Sensebe, L ;

Colombat, P .

BONE MARROW TRANSPLANTATION, 1997, 20 (01) :21-26

[9] Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma [J].

Chau, I ;

Harries, M ;

Cunningham, D ;

Hill, M ;

Ross, PJ ;

Archer, CD ;

Norman, AR ;

Wotherspoon, A ;

Koh, DM ;

Gill, K ;

Uzzell, M ;

Prior, Y ;

Catovsky, D .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :970-977

[10] Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma [J].

Chen, Robert ;

Palmer, Joycelynne M. ;

Thomas, Sandra H. ;

Tsai, Ni-Chun ;

Farol, Len ;

Nademanee, Auayporn ;

Forman, Stephen J. ;

Gopal, Ajay K. .

BLOOD, 2012, 119 (26) :6379-6381

← 1 2 3 4 5 6 7 8 9 →